Molecular Positron Emission Tomography and PET/CT Imaging in Urological Malignancies

European Urology

Volumn 51, Issue 6, 2007, Pages 1511-1521

  Powles, Tom ^a   Murray, Iain ^a   Brock, Cathryn ^a   Oliver, Tim ^a   Avril, Norbert ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

F 18 fluorodeoxyglucose; Diagnosis; Staging; Treatment monitoring; Urological tumours

Indexed keywords

ACETIC ACID; AMINO ACID; CHOLINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TRACER;

AMINO ACID METABOLISM; BLADDER CANCER; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; GERM CELL TUMOR; GLUCOSE METABOLISM; HUMAN; HYPOXEMIA; INFORMATION; KIDNEY CARCINOMA; MEDICAL LITERATURE; METASTASIS; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; TUMOR CELL; TUMOR RECURRENCE; URINARY EXCRETION; URINARY TRACT CANCER;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; UROGENITAL NEOPLASMS;

EID: 34247379134     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.061     Document Type: Review

References (61)

1. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
2. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97 (2000) 9226-9233
3. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
4. Avril N.E., and Weber W.A. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43 (2005) 189-204
5. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., and Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-445
6. Grierson J.R., and Shields A.F. Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27 (2000) 143-156
7. DeGrado T.R., Baldwin S.W., Wang S., et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42 (2001) 1805-1814
8. Koh W.J., Rasey J.S., Evans M.L., et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22 (1992) 199-212
9. Townsend D.W., Carney J.P., Yap J.T., and Hall N.C. PET/CT today and tomorrow. J Nucl Med 45 (2004) 4S-14S
10. Effert P.J., Bares R., Handt S., Wolff J.M., Bull U., and Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 (1996) 994-998
11. Hofer C., Laubenbacher C., Block T., Breul J., Hartung R., and Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 (1999) 31-35
12. Haseman M.K., Reed N.L., and Rosenthal S.A. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: positron emission tomography and biopsy correlation. Clin Nucl Med 21 (1996) 704-713
13. Shreve P.D., Grossman H.B., Gross M.D., and Wahl R.L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199 (1996) 751-756
14. Yeh S.D., Imbriaco M., Larson S.M., et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23 (1996) 693-697
15. Schoder H., Herrmann K., Gonen M., et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11 (2005) 4761-4769
16. Oyama N., Akino H., Suzuki Y., et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 4 (2002) 99-104
17. Morris M.J., Akhurst T., Larson S.M., et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11 (2005) 3210-3216
18. Oyama N., Akino H., Kanamaru H., et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43 (2002) 181-186
19. Kotzerke J., Volkmer B.G., Neumaier B., Gschwend J.E., Hautmann R.E., and Reske S.N. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29 (2002) 1380-1384
20. Fricke E., Machtens S., Hofmann M., et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 (2003) 607-611
21. Oyama N., Miller T.R., Dehdashti F., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44 (2003) 549-555
22. Sandblom G., Sorensen J., Lundin N., Haggman M., and Malmstrom P.U. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67 (2006) 996-1000
23. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
24. Kotzerke J., Prang J., Neumaier B., et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27 (2000) 1415-1419
25. Yamaguchi T., Lee J., Uemura H., et al. Prostate cancer: a comparative study of (11)C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32 (2005) 742-748
26. Kotzerke J., Volkmer B.G., Glatting G., et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42 (2003) 25-30
27. Coleman R., DeGrado T., Wang S., et al. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3 (2000) 147
28. Price D.T., Coleman R.E., Liao R.P., Robertson C.N., Polascik T.J., and DeGrado T.R. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168 (2002) 273-280
29. Kwee S.A., Coel M.N., Lim J., and Ko J.P. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 173 (2005) 252-255
30. Schmid D.T., John H., Zweifel R., et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235 (2005) 623-628
31. Cimitan M., Bortolus R., Morassut S., et al. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33 (2006) 1387-1398
32. Martorana G., Schiavina R., Corti B., et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176 (2006) 954-960 discussion 960
33. Farsad M., Schiavina R., Castellucci P., et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46 (2005) 1642-1649
34. Larson S.M., Morris M., Gunther I., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45 (2004) 366-373
35. Bachor R., Kotzerke J., Gottfried H.W., Brandle E., Reske S.N., and Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 35 (1996) 146-150
36. Goldberg M.A., Mayo-Smith W.W., Papanicolaou N., Fischman A.J., and Lee M.J. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 52 (1997) 510-515
37. Aide N., Cappele O., Bottet P., et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30 (2003) 1236-1245
38. Kang D.E., White Jr. R.L., Zuger J.H., Sasser H.C., and Teigland C.M. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171 (2004) 1806-1809
39. Majhail N.S., Urbain J.L., Albani J.M., et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21 (2003) 3995-4000
40. Shreve P., Chiao P.C., Humes H.D., Schwaiger M., and Gross M.D. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36 (1995) 1595-1601
41. Kosuda S., Kison P.V., Greenough R., Grossman H.B., and Wahl R.L. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 24 (1997) 615-620
42. Drieskens O., Oyen R., Van Poppel H., Vankan Y., Flamen P., and Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1412-1417
43. Bachor R., Kotzerke J., Reske S.N., and Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 38 (1999) 46-50
44. Heicappell R., Muller-Mattheis V., Reinhardt M., et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36 (1999) 582-587
45. Ahlstrom H., Malmstrom P.U., Letocha H., Andersson J., Langstrom B., and Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 37 (1996) 180-185
46. Gofrit O.N., Mishani E., Orevi M., et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 176 (2006) 940-944 discussion 944
47. Wilson C.B., Young H.E., Ott R.J., et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 22 (1995) 508-513
48. Muller-Mattheis V., Reinhardt M., Gerharz C.D., et al. Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe A 37 (1998) 609-620
49. Hain S.F., O'Doherty M.J., Timothy A.R., Leslie M.D., Partridge S.E., and Huddart R.A. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 27 (2000) 590-594
50. Albers P., Bender H., Yilmaz H., Schoeneich G., Biersack H.J., and Mueller S.C. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 53 (1999) 808-811
51. Cremerius U., Wildberger J.E., Borchers H., et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 54 (1999) 900-904
52. Lassen U., Daugaard G., Eigtved A., Hojgaard L., Damgaard K., and Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 30 (2003) 396-402
53. Sanchez D., Zudaire J.J., Fernandez J.M., et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 89 (2002) 912-916
54. Spermon J.R., De Geus-Oei L.F., Kiemeney L.A., Witjes J.A., and Oyen W.J. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 89 (2002) 549-556
55. Tsatalpas P., Beuthien-Baumann B., Kropp J., et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 68 (2002) 157-163
56. Hain S.F., O'Doherty M.J., Timothy A.R., Leslie M.D., Harper P.G., and Huddart R.A. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 83 (2000) 863-869
57. De Santis M., Becherer A., Bokemeyer C., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22 (2004) 1034-1039
58. De Santis M., Bokemeyer C., Becherer A., et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19 (2001) 3740-3744
59. Ganjoo K.N., Chan R.J., Sharma M., and Einhorn L.H. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17 (1999) 3457-3460
60. Pfannenberg A.C., Oechsle K., Kollmannsberger C., et al. Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker. RoFo 176 (2004) 76-84
61. Lawrentschuk N., Poon A.M., Foo S.S., et al. Assessing regional hypoxia in human renal tumours using F-fluoromisonidazole positron emission tomography. BJU Int 96 (2005) 540-546